Cargando…
Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma
PURPOSE: Caspase recruitment domain-containing protein 9 (CARD9) is expressed at high levels in bone marrow cells and has a crucial role in innate immunity. Current studies indicate that CARD9 also plays a key role in tumor progression, but there are few reports on the role of CARD9 in lung cancer....
Autores principales: | Miwa, Nanako, Nagano, Tatsuya, Jimbo, Naoe, Dokuni, Ryota, Kiriu, Tatsunori, Mimura, Chihiro, Yasuda, Yuichiro, Katsurada, Masahiro, Yamamoto, Masatsugu, Tachihara, Motoko, Tanaka, Yugo, Kobayashi, Kazuyuki, Itoh, Tomoo, Maniwa, Yoshimasa, Nishimura, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498929/ https://www.ncbi.nlm.nih.gov/pubmed/32982291 http://dx.doi.org/10.2147/OTT.S265539 |
Ejemplares similares
-
High expression level of serpin peptidase inhibitor clade E member 2 is associated with poor prognosis in lung adenocarcinoma
por: Dokuni, Ryota, et al.
Publicado: (2020) -
Yield of tumor samples with a large guide-sheath in endobronchial ultrasound transbronchial biopsy for non-small cell lung cancer: A prospective study
por: Katsurada, Naoko, et al.
Publicado: (2021) -
Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines
por: Effendi, Wiwin Is, et al.
Publicado: (2019) -
Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020) -
Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non‐small cell lung cancer
por: Tachihara, Motoko, et al.
Publicado: (2020)